COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT
THIS COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is made
the 23rd. day of May, 2011 (“EFFECTIVE DATE”) by and between the LUDWIG
INSTITUTE FOR CANCER RESEARCH LTD, a Swiss not-for-profit corporation, with its
registered office at Stadelhoferstrasse 22, 8001, Zurich, Switzerland, and
having an office at 666 Third Avenue, New York, NY 10017, United States of
America (“LICR”) and 4-ANTIBODY AG (“4AB”), incorporated in Switzerland at
Schwarzwaldallee 215, CH-4002 Basel, Switzerland.

WHEREAS, LICR owns technology and know-how with respect to the development of
immunotherapies including antibodies to treat various forms of cancer; and

WHEREAS, 4AB owns technology and know-how with respect to the generation and
development of human monoclonal antibodies to treat human diseases; and

WHEREAS, LICR and 4AB desire to establish a multi-target research and
development collaboration in a focus area of high interest for the cancer
immunology field of translational research in the immunosuppression and
immunoregulation in cancer; and

NOW THEREFORE, in consideration of the premises, representations, warranties and
agreements set forth herein, the parties hereto agree as follows.

1
DEFINITIONS

1.01
“AFFILIATE” shall mean any corporation or business entity of which LICR or 4AB
owns directly or indirectly, fifty percent (50%) or more of the assets or
outstanding stock, or any corporation which LICR or 4AB directly or indirectly
controls, or any parent corporation which owns, directly or indirectly, fifty
percent (50%) or more of the assets or outstanding stock of LICR or 4AB or
directly or indirectly controls LICR or 4AB.

1.02
“ANTIBODY” or “ANTIBODIES” shall mean an immunoglobulin (Ig) molecule, generally
comprising four polypeptide chains, two heavy (H) chains and two light (L)
chains, or an equivalent Ig homologue thereof (e.g., a camelid nanobody, which
comprises only a heavy chain, single domain antibodies (dAbs) which can be
either heavy or light chain); including full length functional mutants,
variants, or derivatives thereof (including but not limited to chimeric,
veneered, humanized antibodies, fully human equivalents (e.g. created by guided
selection or similar technology), which retain the essential epitope binding
features of an Ig molecule, and including dual specific, bispecific,
multispecific, and dual variable domain immunoglobulins; Immunoglobulin
molecules can be of any class (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), or
subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) and allotype. Also
included within the meaning of the term Antibody is any ANTIBODY FRAGMENT.

1.03
“ANTIBODY FRAGMENT” means a molecule comprising at least one polypeptide chain
that is not full length, including (i) a Fab fragment, which is a monovalent
fragment consisting of the variable light (VL), variable heavy (VH), constant
light (CL) and constant heavy 1 (CH1) domains; (ii) a F(ab')2 fragment, which is
a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at
the hinge region; (iii) a heavy chain portion of a Fab (Fd) fragment, which
consists of the VH and CH1 domains; (iv) a variable fragment (Fv) fragment,
which consists of the VL and VH domains of a single arm of an antibody, (v) a
domain antibody (dAb) fragment, which comprises a single variable domain; (vi)
an isolated complementarity determining region (CDR); (vii) a Single Chain Fv
Fragment; (viii) a diabody, which is a bivalent, bispecific antibody in which VH
and VL domains are expressed on a single polypeptide chain, but using a linker
that is too short to allow for pairing between the two domains on the same
chain, thereby forcing the domains to pair with the complementarity domains of
another chain and creating two antigen binding sites; and (ix) a linear
antibody, which comprises a pair of tandem Fv segments (VH-CH1- VH-CH1) which,
together with complementarity light chain polypeptides, form a pair of antigen
binding regions; and (x) other non-full length portions of heavy and/or light
chains, or mutants, variants, or derivatives thereof, alone or in any
combination.

1.04
“ARBITRATION” shall have the meaning ascribed to it in Section 13.02C.

1.05
“ARBITRATORS” shall have the meaning ascribed to it in Section 13.02C.

1

--------------------------------------------------------------------------------

1.06
“BACKGROUND INTELLECTUAL PROPERTY” shall mean any INTELLECTUAL PROPERTY, owned
or controlled by a party, and which is provided to the other party for use in
the PROGRAM, and/or which is necessary or useful for performing the PROGRAM.

1.07
“CHANGE OF CONTROL” shall mean a situation in which more than fifty percent
(50%) of the ownership interest in a party is acquired by a third party.

1.08
“CLINICAL TRIAL” shall mean any clinical studies, research protocols, or medical
research, wherein a PRODUCT is evaluated as a potential diagnostic or
therapeutic in a human patient or set of patients and the PROTOCOLS of which
LICR starts to execute, after the EFFECTIVE DATE of this Agreement.

1.09
“CUMULATIVE COSTS” shall mean the identified and documented direct costs
incurred by each party directly related to the research and development of each
PRODUCT and direct costs associated with PROGRAM INTELLECTUAL PROPERTY filing,
prosecution, and maintenance covering each PRODUCT. CUMULATIVE COSTS exclude
costs not directly related to the development of a PRODUCT and the PROGRAM
INTELLECTUAL PROPERTY claiming such PRODUCT, and shall stop incurring for a
PRODUCT and the PROGRAM INTELLECTUAL PROPERTY claiming such PRODUCT upon the
earlier of (i) its licensing to a third party; (ii) upon its first regulatory
approval as obtained by 4-AB; (iii) the transfer or assignment of rights to a
PRODUCT or PROGRAM INTELLECTUAL PROPERTY claiming such PRODUCT obtained under or
as a result of this Agreement to a third party. CUMULATIVE COSTS for each such
PRODUCT may be deducted from anything of value received for rights in a PRODUCT
and the PROGRAM INTELLECTUAL PROPERTY claiming such PRODUCT, whether cash or
anything received in lieu of cash for such rights. CUMULATIVE COSTS shall be
disclosed annually to the JOINT MANAGEMENT

COMMITTEE for approval and any unapproved costs shall not be considered CUMULA
TIVE COSTS. For clarity, the CUMULA TIVE COSTS of each PRODUCT and the PROGRAM
INTELLECTUAL PROPERTY, or part thereof, claiming such PRODUCT can only be
deducted from the monetary realization of each such specific instance. By way of
non-limiting example only, CUMULATIVE COSTS associated with PRODUCT 1 shall
exclude expenses related to a clinical trial for development of PRODUCT 2, shall
not include PROGRAM INTELLECTUAL PROPERTY claiming PRODUCT 2, and cannot be
deducted from licensing revenue of PRODUCT 2.

1.10
“DISPUTE” shall have the meaning ascribed to it in Section 13.02A.

1.11
“EFFECTIVE DATE” shall have the meaning ascribed to such term in the
introductory paragraph of this Agreement.

1.12    “EXTENSION TERM” shall have the meaning ascribed to it in Section 2.02.

1.13
“FIELD” shall mean the diagnosis, prevention and treatment of animal and human
diseases or conditions.

1.14    “ICC” shall have the meaning ascribed to it in Section 13.02C.

1.15    “INFORMATION” shall have the meaning ascribed to it in Section 6.01.

1.16    “INITIAL TERM” shall mean three (3) years from the EFFECTIVE DATE.

1.17
“INTELLECTUAL PROPERTY” shall mean the rights comprised in any patent,
copyright, design, trade mark, eligible layout or similar right whether at
common law or conferred by statute, rights to apply and applications for
registration under a statute in respect of these or like rights and rights to
protect trade secrets and know-how, throughout the world for the full period of
the rights and all renewals and extensions.

1.18
“JOINT MANAGEMENT COMMITTEE” shall mean the committee established pursuant to
Section 3 herein.

1.19
“LICR” shall have the meaning ascribed to such term in the introductory
paragraph of this Agreement.

1.20
“4AB” shall have the meaning ascribed to it in the introductory paragraph of
this Agreement.

1.21
“NY LAB” shall mean LICR’s laboratory at Memorial Sloan-Kettering Cancer Center,
1275 York Avenue, Box 32, New York, New York 10021-6007, USA. The research at
the NY LAB is governed by an interinstitutional agreement between LICR and
Memorial Sloan-Kettering Cancer Center (MSKCC). A redacted version of that
agreement is attached in Appendix 6 (“MSKCC AGREEMENT”).

1.22
“PROCEEDS” shall mean all forms of cash consideration such as but not limited to
license fees, royalties, milestone fees and sublicense fees and all forms of
non-cash consideration received from a licensee or similar

2

--------------------------------------------------------------------------------

third party as a result of the commercialization of PRODUCTS, PROGRAM
INTELLECTUAL PROPERTY and PROGRAM PATENTS. PROCEEDS shall not include
consideration received as research funding the research and development of a
PRODUCT.

1.23
“PRODUCT(S)” shall mean any ANTIBODY or ANTIBODIES or any other product,
service, process or method of using such ANTIBODY or ANTIBODIES which recognizes
a TARGET.

1.24
“PROGRAM” as used herein shall mean the collaboration between LICR and 4AB to
carry out the research and clinical development program set out in Appendix 1.
The PROGRAM will cover and include all monoclonal ANTIBODIES recognizing a
TARGET, generated by 4AB during the INITIAL TERM or any EXTENSION TERM of the
research program as specified Appendix 1.

1.25
“PROGRAM INTELLECTUAL PROPERTY” shall mean all ANTIBODIES results, research
data, know-how, materials, compounds and inventions which are created solely by
the LICR or 4AB during the course of and as a direct result of carrying out the
PROGRAM.

1.26
“PROGRAM P A TENT(S)” shall mean all patents issued and patent applications
filed pertaining to the PROGRAM INTELLECTUAL PROPERTY during the TERM, and any
reissues, re-examinations, continuations, claims of U.S. and foreign
continuations-in-part which are directed to subject matter specifically
described in the U.S. and foreign patent applications, divisions, renewals, or
renewals claiming priority to any such patent or patent application and
including any extensions, patents of addition, and any extension of the term of
the patent or supplementary protection certificate or other means by which
greater effective patent protection is extended.

1.27
"PROTOCOL" shall mean a document or set of documents that describes for example
and without limitation the objective(s), design, methodology, statistical
considerations, and organization of one or more CLINICAL TRIAL(s).

1.28
“RULES” shall have the meaning ascribed to it in Section 13.02C.

1.29
“TARGETS” shall mean the cell surface proteins against which ANTIBODIES shall be
generated and evaluated within the PROGRAM, which shall be selected by the JOINT
MANAGEMENT COMMITTEE. TARGETS shall be identified in Appendix 2, which shall be
updated from time to time as agreed by the JOINT MANAGEMENT COMMITTEE.

1.30
“TERM” shall have the meaning ascribed to it in Section 9.01.

1.31
“TERRITORY” shall mean all countries worldwide, their territories and
possessions.

3

--------------------------------------------------------------------------------

2    RESEARCH COLLABORATION AND DEVELOPMENT

2.01
LICR and 4AB shall carry out the PROGRAM in accordance with the research and
clinical development program set out in Appendix 1. LICR and 4AB shall perform
the PROGRAM in accordance with the timelines set forth therein, as reasonably
practicable, and shall perform the PROGRAM using the highest professional
standards of workmanship and care in so doing. LICR and 4AB shall not deviate
materially from the PROGRAM without the prior written consent of the other
party.

2.02
The PROGRAM shall commence on the EFFECTIVE DATE and shall continue for the
INITIAL TERM; provided, however, that with the consent of both LICR and 4AB,
which consent shall not be unreasonably withheld, the PROGRAM may be extended
for an additional period of up to three (3) years beyond the INITIAL TERM (the
“EXTENSION TERM”). Further extensions may be mutually agreed upon by the
parties.

•

2.03
The PROGRAM may be modified only by mutual written consent of the parties.

2.04
Any CLINICAL TRIAL conducted as part of the PROGRAM shall comply with the
following provisions:

A: Any CLINICAL TRIAL shall only be initiated following written approval of the
corresponding PROTOCOL by the JOINT MANAGEMENT COMMITTEE.
B: Any PROTOCOL amendment must be approved in writing by the JOINT MANAGEMENT
COMMITTEE, unless more timely amendments are required by a regulatory authority.
C: Each CLINICAL TRIAL approved by the JOINT MANAGEMENT COMMITTEE will be
governed by a separate and independent written clinical trial agreement which
shall be negotiated in good faith between LICR and 4AB.

2.05
Subject to any further written agreement between the parties, each party shall
be responsible for its own costs and expenses incurred in performing its
research and development activities as described the PROGRAM.

3    JOINT MANAGEMENT COMMITTEE

3.01
The parties shall establish and maintain a JOINT MANAGEMENT COMMITTEE to monitor
the conduct, management, supervision and progress of the PROGRAM so as to
provide the best chance of a successful outcome for the research and development
of PRODUCT(S). The JOINT MANAGEMENT COMMITTEE responsibilities shall include:

A: Preparing and approving annual research plans for the PROGRAM
B: Exchanging annual research budgets and approval of CUMULATIVE COSTS on a
regular basis
C: Discussing progress and exchanging results of the PROGRAM
D: Preparation and approval of PROTOCOL(s) for any CLINICAL TRIAL(s) and
approval of any PROTOCOL amendment to any CLINICAL TRIAL
E: Discussing the potential creation or existence of any PROGRAM INTELLECTUAL
PROPERTY and agreeing a plan for protecting such PROGRAM INTELLECTUAL PROPERTY
F: Discussing and reviewing proposed publications and disclosures by either
party

G: Discussing and reviewing the commercialization of the PRODUCTS and PROGRAM
PATENTS

3.02
The JOINT MANAGEMENT COMMITTEE shall consist of representatives from 4AB and
LICR, provided that the number of representatives of each of them will at all
times be and remain equal. The parties will have the right to change their
representatives from time to time by notifying one another to this effect. 4AB
and LICR shall each appoint a project coordinator from one of its
representatives who shall report to the JOINT MANAGEMENT COMMITTEE as required.

3.03
Each member of the JOINT MANAGEMENT COMMITTEE may appoint an alternate and
references in this paragraph and in this Section to “members” and
“representatives” of the JOINT MANAGEMENT COMMITTEE shall include references to
alternates of such members and representatives. An alternate will only act if
the member is not available.

3.04
The JOINT MANAGEMENT COMMITTEE shall meet, at least once per calendar quarter,
in person, via teleconferences, or via videoconference and shall hold such
additional meetings as its members think fit.

3.05
Unless otherwise agreed by the parties, 4AB shall appoint a Chairperson of the
JOINT MANAGEMENT COMMITTEE who shall be responsible for preparing the minutes of
JOINT MANAGEMENT COMMITTEE meetings as well as any related correspondence.

4

--------------------------------------------------------------------------------

3.06
No business shall be transacted at any meeting of the JOINT MANAGEMENT COMMITTEE
unless a quorum of members is present at the time when the meeting proceeds to
business. A quorum shall be at least four (4) members present in person or by
their alternate, at least two (2) of whom must be representatives appointed by
4AB and at least two (2) of whom must be representatives appointed by LICR.

3.07
All matters and all formal resolutions of the JOINT MANAGEMENT COMMITTEE shall
require the approval of both parties acting through their respective JOINT
MANAGEMENT COMMITTEE members. In the event of any disagreement amongst the
members of the JOINT MANAGEMENT COMMITTEE with respect to any aspect of the
PROGRAM, the matter of disagreement shall be resolved in accordance with the
dispute resolution process set out in Section 13.

3.08
The first representatives of the JOINT MANAGEMENT COMMITTEE nominated by 4AB and
LICR shall be as set forth in Appendix 3 hereto.

3.09
The JOINT MANAGEMENT COMMITTEE shall ensure that care is taken to properly
record and document all research and development activities performed during the
PROGRAM. Each party shall promptly notify the JOINT MANAGEMENT COMMITTEE in
writing of the potential creation or existence of any PROGRAM INTELLECTUAL
PROPERTY.

4 COMMERCIALIZATION

4.01
4AB shall have the sole right to negotiate with prospective licensee’s
exclusive, sub- licensable, worldwide licenses or options, under the PROGRAM
INTELLECTUAL PROPERTY and PROGRAM P A TENTS to develop and commercialize
PRODUCTS, in accordance with the terms of this Agreement.

4.02
4AB shall keep LICR informed in writing on a regular basis concerning its
progress in securing the exploitation of the PRODUCTS and PROGRAM INTELLECTUAL
PROPERTY and the status of negotiations with prospective licensees. 4AB shall
provide LICR with copies of draft term sheets and license proposals being
exchanged with prospective licensees.

4.03
LICR shall provide such assistance as is reasonably necessary for 4AB to carry
out its rights and responsibilities under this section 4.

4.04
4AB shall not grant any license or option under PROGRAM INTELLECTUAL PROPERTY
and PROGRAM PATENTS to develop and commercialize PRODUCTS without the written
consent of LICR, which consent shall not be unreasonably withheld or delayed.

4.05
4AB shall provide LICR with copies of all executed license agreement and annual
diligence reports of licensee’s efforts to develop and commercialize licensed
PRODUCTS and PROGRAM PATENTS

4.06
LICR on behalf of itself and its academic collaborators and Memorial
Sloan-Kettering Cancer Center and its academic collaborators retain an
irrevocable right to practice only for their educational and non-commercial
research (including clinical research involving patient care) purposes the
inventions claimed under PROGRAM INTELLECTUAL PROPERTY and PROGRAM PATENTS,
where any clinical trial using an ANTIBODY generated and developed through the
PROGRAM will be conducted under a JOINT MANAGEMENT COMMITTEE agreed PROTOCOL.

4.07
4AB acknowledges that LICR, after publication or presentation of scientific data
related to the PROGRAM, may have obligations to share materials, including
ANTIBODIES, with the academic scientific community. In such cases the ANTIBODIES
shall be made available to other academic researchers, solely for non-
commercial research and educational purposes, pursuant to a material transfer
agreement in the form set out in the template agreement in Appendix 5, with any
proposed changes thereto subject to the prior review and written approval of
4AB, which shall not be unreasonably withheld.

4.08
The parties acknowledge that the United States Government, as a matter of
statutory right under 35 USC Sections 200-212, may hold a non-exclusive license
and certain other rights under PROGRAM PATENTS made as a consequence of the use
of funding supplied by the United States Government for the PROGRAM. In the
event the United States Government has such rights or in the future is found to
have such rights with respect to any license contemplated under this Agreement,
even if termed an “exclusive” license, shall be understood to be subject to the
rights of the United States Government, without any effect on the parties’
remaining obligation, as set forth in this Agreement.

5

--------------------------------------------------------------------------------

4.09
No rights or licenses (either express or implied) to any intellectual property
rights or any proprietary technical information of LICR or 4AB are granted by
this Agreement, except as expressly provided in this Section 4 or the following
Section 5.

5    INTELLECTUAL PROPERTY

5.01
All rights, title and interest in and to any BACKGROUND INTELLECTUAL PROPERTY
shall remain with the party owning such BACKGROUND INTELLECTUAL PROPERTY. Each
party grants the other party a royalty free, non- exclusive license to use its
BACKGROUND INTELLECTUAL PROPERTY only for the purpose of carrying out the
PROGRAM. Neither party may grant any sublicense to use the other party’s
BACKGROUND INTELLECTUAL PROPERTY to any third party without the other party’s
written agreement.

5.02
PROGRAM INTELLECTUAL PROPERTY and PROGRAM PATENTS shall be jointly owned in
equal shares by 4AB and LICR, subject to LICR’s obligations under the MSKCC
AGREEMENT.

5.03
During the TERM and EXTENSION TERM, the JOINT MANAGEMENT COMMITTEE shall assess
the PROGRAM INTELLECTUAL PROPERTY with regard to any inventions that could be
the subject of a patent application, and where considered appropriate 4AB will
file patent application(s) in those countries agreed to by the parties. All such
patent applications will become PROGRAM PATENTS as part of the PROGRAM
INTELLECTUAL PROPERTY. The inventorship of all such PROGRAM PATENTS shall be
determined under US patent law.

5.04
During the INITIAL TERM and any EXTENSION TERM, 4AB will be responsible for
managing the filing and prosecutions of any patents or applications for patents
included in the PROGRAM PATENTS at 4AB’s cost. LICR and 4AB shall consult
regularly in the preparation, filing, prosecution and maintenance of any patents
or applications for patents included in the PROGRAM PATENTS, and share copies of
all material correspondence and filings (and any other information requested by
a party) related thereto. 4AB may, in its sole discretion, notify LICR that it
does not desire continued filing, prosecution or maintenance of any PROGRAM
PATENT upon which timely notification LICR shall have the option to continue the
prosecution or maintenance of the PROGRAM PATENT at its sole expense. If LICR
does not provide written notice of such intent within 30 days of such notice
from 4AB, then 4AB shall have no further responsibility for the costs thereof,
and such patent shall no longer be deemed a PROGRAM PATENT.

5.05
4AB and LICR shall reasonably discuss the need to enforce and/or defend the
PROGRAM PATENTS and PROGRAM INTELLECTUAL PROPERTY against any third party that
infringes or wrongfully uses the same in any manner, and only after 4AB and LICR
have agreed a course of action shall any action be initiated by either party.

5.06
The parties hereto shall cooperate with each other in gaining patent term
restoration or similar extensions or continuations of rights in the TERRITORY
where applicable to PROGRAM PATENT(S).

6    CONFIDENTIALITY

6.01
All oral, written, electronic or other communications and other information
disclosed or provided by the parties including any and all analyses or
conclusions drawn or derived therefrom regarding any PROGRAM INTELLECTUAL
PROPERTY or the PROGRAM, or either party’s assays, processes, formulations,
analytical procedures, clinical procedures, methodologies, products, samples,
material, cells and specimens or functions (“INFORMATION”) shall be received and
used solely for the purposes set forth in this Agreement and subject to the
following terms and conditions:

A.
Each party shall keep the other’s INFORMATION in confidence for the period
commencing on the EFFECTIVE DATE and ending five (5) years after the end of the
TERM or EXTENSION TERM and will not, without the disclosing party’s prior
written consent, disclose any INFORMATION to any person or entity, except those
of the receiving party’s officers, employees, consultants and AFFILIATES who
require said INFORMATION to perform their obligations under this Agreement. Each
of the party’s officers, employees, consultants and AFFILIATES to whom
INFORMATION is to be disclosed shall be advised by the receiving party of, and
bound by the terms of this Agreement.

B.
The obligations of confidentiality and non-use set forth herein shall not apply
to any INFORMATION which is:

i
known to the receiving party prior to receipt from the disclosing party, other
than through prior disclosure by the disclosing party, as evidenced by the
receiving party’s written records;

6

--------------------------------------------------------------------------------

ii
available to the general public or which hereafter becomes available to the
general public otherwise than through a breach of this Agreement;

iii
obtained by the receiving party from a third party with a valid right to
disclose such INFORMATION, provided that said third party is not under a
confidentially obligation to the disclosing party; or

    
iv
independently developed by employees, agents, consultants or AFFILIATES of the
receiving party who had no knowledge of or access to the disclosing party’s
INFORMATION as evidenced by the receiving party’s written records.

C.
The parties will keep the terms of this Agreement and to the extent necessary or
desirable to protect any INTELLECTUAL PROPERTY arising in connection with the
PROGRAM, the PROGRAM and PROGRAM INTELLECTUAL PROPERTY, confidential except as
otherwise agreed.

D.
The parties may, under appropriate obligations of confidentiality, disclose the
PROGRAM INTELLECTUAL PROPERTY and the terms of this Agreement to its advisers
and consultants, and to its potential and actual collaborators, investors,
shareholders and licensees.

E.
Except as is set forth in this Agreement, all INFORMATION shall remain the
proprietary property of the disclosing party.

        
F.
If, in the opinion of the receiving party’s counsel, any of the disclosing
party’s INFORMATION is required to be disclosed pursuant to law, regulation, or
court order, the receiving party shall give the disclosing party prompt, written
notice in order to allow the disclosing party to take whatever action it
reasonably deems necessary to protect its INFORMATION. In the event that no
protective order or other remedy is obtained, or the disclosing party waives
compliance with the terms of this Section 6, receiving party will furnish only
that portion of the INFORMATION which receiving party is advised by counsel is
legally required.

G.
Except as is set forth in this Agreement, no party shall acquire any license or
other intellectual property interest in any INFORMATION disclosed to it by the
other party. Further, except as is set forth in this Agreement, disclosure of
INFORMATION shall not result in any obligation on the part of the discloser to
grant the receiving party any right in or to such INFORMATION.

H.
Upon expiration or termination of this Agreement, each party shall immediately
return to each disclosing party all INFORMATION which it has received from the
disclosing party, all notes which may have been made regarding said information,
and all copies thereof. The receiving party may retain one copy of each item of
INFORMATION, and notes regarding the same, provided that said copy shall be
retained and used solely for the purposes of ongoing compliance with this
Agreement and shall be held in the receiving party’s confidential files. For
purposes of this paragraph, LICR and 4AB shall be the disclosing parties with
respect to any PROGRAM INTELLECTUAL PROPERTY.

7    CONSIDERATION

7.01
PROCEEDS received by 4AB shall be first used to reimburse each party’s
CUMULATIVE COSTS incurred in respect to the licensed PRODUCT and PROGRAM PATENTS
from which the PROCEEDS are derived.

7.02
The remaining PROCEEDS (“NET PROCEEDS”) shall be shared [**] between LICR and
4AB.

7.03
4AB shall provide LICR its share of CUMULATIVE COSTS and NET PROCEEDS within
thirty (30) days of its receipt of any PROCEEDS, together with a report
disclosing detail of the PROCEEDS received and the calculation of CUMULATIVE
COSTS and NET PROCEEDS distributed to each party.

8    PAYMENTS

8.01
All payments to be made under this Agreement to LICR shall be made within sixty
(60) days of receipt of a tax invoice from LICR and shall be made in US Dollars
(USD) by bank wire transfer to LICR’s bank account as follows:

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the Commission.

7

--------------------------------------------------------------------------------

Beneficiary/Payee:    Ludwig Institute for Cancer Research Ltd.
Account No.:        
With:            Credit Suisse
Postfach
CH-8070 Zurich, Switzerland
Clearing:
SWIFT:
IBAN:

8.02
If any payment is not made on or before the due date specified herein, 4AB will
pay interest on the outstanding amount until paid in full if requested to do so
by LICR. Interest will be charged at a rate equal to the "Intended Federal Funds
Rate" or equivalent [**] as specified by the Federal Open Market Committee and
currently published by the US Federal Reserve Board at
www.federalreserve.gov/fomc/fundsrate.htm.

8.03
During the TERM and for a period of five (5) years thereafter, 4AB shall keep
complete and accurate records pertaining to the development, manufacture, use,
sale or other disposition of the PRODUCTS, in sufficient detail to permit LICR
to confirm the accuracy of all payments due hereunder and compliance with all
responsibilities and obligations. LICR shall have the right to cause an
independent, certified public accountant to audit such records. Such audits may
be exercised once each calendar year and only with respect to the then current
calendar year and the immediately prior two calendar years, upon reasonable
prior written notice to 4AB and during normal business hours, and LICR shall
bear the full cost of such audit, unless such inspection leads to the discovery
of a discrepancy of greater than the greater of [**] percent ([**] %) in
reporting to LICR's detriment, or of $[**], for any calendar year. In such
instance, 4AB agrees to pay the reasonable cost of such audit plus interest as
stipulated in Section 8.02 from and after the date the audit report is delivered
to4AB. The terms of this Section 8.03 shall survive any termination or
expiration of this Agreement for a period of five (5) years.

9    TERM AND TERMINATION

9.01
This Agreement shall be effective as of the EFFECTIVE DATE and unless terminated
earlier in accordance with this Agreement, shall remain in force until the
expiration of the INITIAL TERM or EXTENSION TERM (the “TERM”).

9.02
Each party shall have the right to terminate this Agreement upon written notice
to the other party if, after receiving written notice of a material breach of
this Agreement, the breaching party fails to cure such breach within sixty (60)
days from the date of such notice and such termination is affirmed by an
arbitral tribunal pursuant to Section 13.

9.03
Either party may terminate this Agreement with notice if the other party makes
an assignment for the benefit of creditors, is the subject of proceedings in
voluntary or involuntary bankruptcy instituted on behalf of or against such
party, or has a receiver or trustee appointed for all or substantially all of
its property; provided that in the case of an involuntary bankruptcy proceeding
such right to terminate shall only become effective if the party consents to the
involuntary bankruptcy or such proceeding is not dismissed within ninety (90)
calendar days after the filing thereof.

9.04
Sections 4 (Commercialization), 5 (Intellectual Property), 6 (Confidentiality),
7 (Consideration), 8 (Payments), 10 (Rights Upon Termination), 12 (Indemnity),
13 (Dispute Resolution), 14 (Public Announcements and Publications), 16
(Survival and Waivers) and 17 (Governing Law) shall survive the expiry or
termination of this Agreement.

10    RIGHTS UPON TERMINATION

10.01
If this Agreement is terminated by 4AB pursuant to Section 9.02 or 9.03, then on
the effective date of said termination, 4AB’s and LICR’s obligations and rights
under this Agreement shall terminate.

Notwithstanding the preceding sentence, 4AB shall retain a fully paid up,
royalty free, perpetual, worldwide, exclusive license under any PROGRAM
PATENT(S). However, notwithstanding such termination, termination of this
Agreement shall not affect any already licensed PRODUCTS and PROGRAM PATENT(S).

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the Commission.

8

--------------------------------------------------------------------------------

10.02
If this Agreement is terminated by LICR pursuant to Section 9.02 or 9.03, then
on the effective date of said termination, 4AB’s and LICR’s obligations and
rights under this Agreement shall terminate. Notwithstanding the preceding
sentence, LICR shall retain a fully paid up, royalty free, perpetual, worldwide,
exclusive license under any PROGRAM PATENT(S). However, notwithstanding such
termination, termination of this Agreement shall not affect any already licensed
PRODUCTS and PROGRAM PATENT(S).

10.03
Notwithstanding termination of this Agreement by either party, each party shall
remain liable to the other with respect to any obligations which arise prior to
the effective date of termination.

11    REPRESENTATIONS AND WARRANTIES

11.01    Each party represents and warrants to the other party that:

A.
it is duly organized and validly existing under the laws of its jurisdiction of
incorporation or formation, and has full corporate or other power and authority
to enter into this Agreement and to carry out the provisions hereof;

B.
it is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder, and the person or persons executing this Agreement on its
behalf have been duly authorized to do so by all requisite corporate or
partnership action;

C.
(i) this Agreement is legally binding upon it and enforceable in accordance with
its terms, and (ii) the execution, delivery and performance of this Agreement by
it does not conflict with any agreement, instrument or understanding, to which
it is a party or by which it may be bound, or violate any material law or
regulation of any court, governmental body or administrative or other agency
having jurisdiction over it; and

D.
it has not, and will not during the TERM OR EXTENSION TERM, grant any right to
any third party that would conflict with the rights granted to the other party
hereunder.

12    INDEMNITY & INSURANCE

12.01
LICR shall indemnify, hold harmless and defend 4AB and its directors, officers,
agents and employees from and against any loss, costs (including reasonable
attorney’s fees), damages, injury, liability, claims, demands, or causes of
action (“LIABILITY”) arising out of or resulting from (a) personal injury or
death in connection with LICR’s activities hereunder; (b) LICR’s use, handling,
storage or disposal of any materials or information; (c) any negligent act or
omission or willful misconduct of LICR or LICR’s employees or agents; (d) any
act or omission of LICR as an employer; or (e) any debt or other duty of any
kind or amount owed to a LICR subcontractor, except to the extent that any such
LIABILITY is incurred as a result of the gross negligence or willful misconduct
of 4AB.

12.02
4AB shall indemnify, hold harmless and defend LICR and Memorial Sloan-Kettering
Cancer Center and their directors, officers, agents and employees, from and
against any LIABILITY arising out of or resulting from (a) personal injury or
death in connection with 4AB’s activities hereunder; (b) 4AB’s use, handling,
storage or disposal of any materials or information; (c) any negligent act or
omission or willful misconduct of 4AB or 4AB’s employees, or agents; (d) any act
or omission of 4AB as an employer; (e) any debt or other duty of any kind or
amount owed to a 4AB subcontractor; or (f) arising out of this Agreement, except
to the extent that any such LIABILITY is incurred as a result of the gross
negligence or willful misconduct of any such indemnitee. This indemnification
shall also include, but not be limited to, any product liability.

12.03
4AB shall maintain insurance with limits, which are consistent with industry
standards to cover 4AB’s activities in connection with this Agreement.

12.04
Except as otherwise expressly set forth in this Agreement, neither party makes
any representations and extends no warranties of any kind, either express or
implied, including but not limited to warranties of merchantability, fitness for
a particular purpose, validity of patent rights claims issued or pending, or
non-infringement of third party rights.

13 DISPUTE RESOLUTION

9

--------------------------------------------------------------------------------

13.01
The parties recognize that disputes as to certain matters may from time to time
arise which relate to the rights of either party and obligations hereunder. It
is the objective of the parties to establish procedures to facilitate the
resolution of such disputes in an expedient manner by mutual cooperation and
without resort to litigation. To accomplish this objective, the parties agree to
follow the procedures set forth in Section 13.02, if and when such a dispute
arises between the parties.

13.02    Dispute Resolution Procedures.

A.
If any dispute, claim or controversy of any nature arising out of or relating to
this Agreement, including any action or claim based on tort, contract or
statute, or concerning the interpretation, effect, termination, validity,
performance and/or breach of this Agreement (each, a “DISPUTE”), arises between
the parties and the parties cannot resolve such DISPUTE within thirty (30) days
of a written request by either party to the other party, the parties agree to
refer the DISPUTE either to: (a) the chief scientific officer (or equivalent) of
LICR and the chief scientific officer (or equivalent) of 4AB for resolution (if
such DISPUTE relates to scientific issues); or (b) to the head of business
development (or equivalent) of LICR and the head of business development (or
equivalent) of 4AB for resolution (if such DISPUTE does not relate to scientific
issues). If such officers of the parties cannot resolve such DISPUTE within an
additional thirty (30) days, then such DISPUTE shall be referred to the chief
executive officer (or equivalent) of LICR and the chief executive officer (or
equivalent) of 4AB for resolution. After an additional thirty (30) days, if such
officers have not succeeded in negotiating a resolution of the DISPUTE, then
either party may at any time thereafter seek to resolve such DISPUTE by
arbitration pursuant to Section 13.02C below.

B.
The parties acknowledge and agree that any declarations (either oral or in
writing) rendered by the parties’ representatives during the resolution
procedure under Section 13.02A above, shall not be considered as an
acknowledgement of such party’s liability in respect to the DISPUTE. The parties
agree that neither of them may rely on such statement or document as mean of
evidence during the arbitration proceeding. For the avoidance of doubts, this
Section 13.02B shall not apply to documents, information and statements relating
to the disputed obligations under this Agreement.

C.    If any dispute, disagreement, claim or controversy of any nature or type
arises out of or results from this Agreement and is not resolved pursuant to
Section 13.02A, then without regard or reference to the principles of conflicts
of law or international private law or any contrary term or condition in any
international treaty or convention (other than in connection with the
recognition of arbitral awards as the parties have agreed below):

i    Jurisdiction/Forum. Any DISPUTE that cannot be resolved after negotiation
between the parties as set forth in Section 13.02A shall be finally resolved by
binding arbitration under the Rules of Arbitration of the International Chamber
of Commerce (“ICC”) as supplemented by clause “v”, below (collectively, the
“RULES”).

ii    Applicability of Rules. If a procedural question or dispute arises that is
not governed by the RULES, the ARBITRATORS shall make a binding determination of
its resolution after affording each party an opportunity to state its preferred
means of resolution. Each party hereby expressly, irrevocably and
unconditionally consents and submits to the personal jurisdiction of the ICC and
waives and hereby affirmatively covenants not to assert their right to object to
or challenge the sole and exclusive personal jurisdiction of the ICC in
connection with DISPUTES. Any controversy concerning the extent to which any
DISPUTE is subject to the terms and conditions of this Section and/or the RULES,
or concerning the applicability, interpretation, or enforceability of this
Section and/or the RULES, including any contention that all or part of these
procedures are invalid or unenforceable, shall be governed by the substantive
laws of England and Wales.

iii    Venue, Language and Governing Law. The arbitration described herein (the
“ARBITRATION”) shall be conducted in the English language and all written briefs
and statements prepared by the parties shall be submitted in the English
language. The ARBITRATION shall be conducted at a mutually agreed location in
England and Wales. All DISPUTES shall be governed by and construed in accordance
with the substantive laws of England and Wales, and the ARBITRATION shall be
conducted under the procedural requirements of the RULES, all without regard or
reference to principles of conflicts of law that would result in the application
of the laws of another jurisdiction.

iv    Arbitrators. The panel of arbitrators shall consist of three (3) neutral
arbitrators who are mutually agreed upon by the parties meeting the following
criteria: (i) none of them shall be current or former employees, directors or
shareholders of, or otherwise have any current or previous relationship

10

--------------------------------------------------------------------------------

with, either party or its respective AFFILIATES; and (ii) all of them shall be a
person expert in pharmaceutical industry research and development or in
licensing arrangements in the biotechnology or pharmaceutical fields
(collectively, the “ARBITRATORS”). If the parties cannot mutually agree on the
ARBITRATORS within fifteen (15) business days of the filing of the claim with
the ICC, then the parties shall each submit six (6) curriculum vitae of proposed
ARBITRATORS to the International Court of Arbitration of the ICC and that body
shall appoint the ARBITRATORS by selecting one (1) of the expert ARBITRATORS
from each of parties’ submissions and appointing the third ARBITRATOR in its
discretion.

v    Supplemental Rules. The ARBITRATION shall be subject to the following
rules: (i) the ARBITRATORS may not award or assess punitive damages against
either party except that the ARBITRATORS, in their solediscretion, may award
reasonable costs, expenses and fees to the prevailing party; (ii) until such
time as an award of costs is made by the ARBITRATORS, each party shall bear its
own costs and expenses of the ARBITRATION and one-half (1/2) of the fees and
costs of the ARBITRATORS; and (iii) time is of the essence with regard to the
completion of the ARBITRATION and the ARBITRATORS shall make a final award no
later than one (1) year after the filing of the initial claim with the ICC.

vi    Award. The ARBITRATORS’ award shall be the sole and exclusive remedy
between the parties regarding any claims, counter-claims, issues or accountings
presented or pled to the ARBITRATORS, including any such claims, counter-claims,
issues or accountings seeking declaratory, equitable and/or injunctive relief,
and all costs, fees or taxes incident to enforcing the ARBITRATORS’ award shall
be, to the maximum extent permitted by law, charged against the party resisting
enforcement. Judgment upon the award of the ARBITRATORS may be entered in a
court of competent jurisdiction, or application may be made to such court for a
judicial acceptance of the award or any order of enforcement. Without limiting
the foregoing, if and to extent that the final award of the ARBITRATORS is found
unenforceable, either party may bring a cause of action against the other party
before any court of competent jurisdiction at the domicile of the defendant
party.
    
vii    Interim Relief. By agreeing to arbitration, the parties do not intend to
deprive any court of its jurisdiction to issue a pre-arbitral injunction, pre-
arbitral attachment or other order in aid of the arbitration proceedings and the
enforcement of any award. Without prejudice to such provisional remedies in aid
of arbitration as may be available under the jurisdiction of a court, the
ARBITRATORS shall have full authority to grant provisional remedies and to award
damages for the failure of any party to respect the ARBITRATORS’ orders to that
effect.

D.
Notwithstanding anything to the contrary, if any DISPUTE arises from either
party’s rights or obligations under Section 6 (Confidentiality), then a party
may seek equitable relief from a court of competent jurisdiction without needing
to resort to the dispute resolution mechanism described above in this Section
13.02. In the event of any dispute relating to this Agreement or breach thereof,
the parties shall use their best endeavors to develop practical solutions of
mutual benefit to settle conflicts amicably between themselves.

14    PUBLIC ANNOUNCEMENTS AND PUBLICATION

14.01
Neither party shall use the name of the other party in any publicity,
advertising, or news without the prior written consent of the other party.

14.02
4AB and LICR may issue one or more joint announcements regarding this Agreement,
provided each such announcement has been approved in writing by both LICR and
4AB prior to its release. Further, each party may, in presentations;
publications or other disclosures accurately report that it is a party to the
relationship represented by this Agreement. All public announcements and
statements concerning the research, development and commercialization of
PRODUCT(s) by 4AB, LICR or their licensee(s) will acknowledge 4AB’s and LICR’s
role in the discovery and validation of the ANTIBODY or ANTIBODIES.

14.03
It is accepted by the parties that the parties may wish to publish or disclose
aspects of the PROGRAM and results thereof in scientific journals or meetings or
the like. Specifically, LICR and its academic collaborators shall have the right
to publish and present scientific findings relating to the PROGRAM. In such an
event the disclosing party shall provide the other party with copies of such
publications and presentations at least thirty (30) calendar days prior to
submission for publication or presentation. The non-disclosing party shall,
within a period of thirty (30) calendar days of receipt of such publications or
presentations advise the disclosing party whether patent or commercial interests
may be prejudiced by the proposed publication or presentation, in which case the
party shall delay, or cause its collaborators to delay, submission, if
necessary, of the publication or presentation for an

11

--------------------------------------------------------------------------------

additional period, such period not exceeding forty five (45) calendar days, from
notification received from disclosing party. If non-disclosing party has not
responded to the disclosing party within the initial thirty (30) calendar day
time period, the proposed publication or presentation shall be deemed not to
prejudice any patent or commercial interests and the LICR and its academic
collaborators are free to proceed.

15    INDEPENDENT PARTIES

15.01
At all times, 4AB and LICR shall be deemed and shall in fact be independent of
one another and neither shall be authorized or empowered hereby to act as the
agent for the other party for the purpose whatsoever or, on behalf of the other,
enter into any contract, warranty or representations as to any matter.

16    SURVIVAL AND WAIVERS

16.01
The covenants of the parties which by their terms or express intent are to be
performed after the termination or expiration of this Agreement shall survive
the termination or expiration of this Agreement.

16.02
Any term or condition of this Agreement may be waived or qualified at any time
by the party entitled to the benefit thereof by written instrument executed by
said party. No delay or failure on the part of either party in exercising any
rights hereunder, and no partial or single exercise thereof, shall constitute a
waiver of such rights or of any other rights hereunder.

17    GOVERNING LAW

17.01
This Agreement shall be construed and governed in accordance with the laws of
the England and Wales, without regard to its conflicts of law provisions.

18    ASSIGNMENT

18.01
This Agreement, and the rights and obligations hereunder, may not be assigned or
transferred by either party without the prior written consent of the other
party, except in the case of a CHANGE OF CONTROL.

18.02    Any assignment in violation of this provision shall be void.

19    SEVERANCE

19.01
If any provision of this Agreement is held to be invalid or unenforceable by a
court of competent jurisdiction, all other provisions shall continue in full
force and effect.

20    NOTICES

20.01
Any notice or other communication required or permitted to be given to either
party hereto shall be in writing unless otherwise specified and shall be deemed
to have been properly given and effective: (a) on the date of delivery if
delivered in person; (b) the date of electronically confirmed facsimile
transmission if during the recipient’s normal business hours, or otherwise on
the next business day of the recipient; (c) one (1) business day after sending
via next business day delivery by a nationally recognized overnight courier
service; or (d) three (3) days after mailing by registered or certified mail,
postage prepaid and return receipt requested, to the other party at the
following address or facsimile number.

Notices to LICR shall be addressed to:

Ludwig Institute for Cancer Research Ltd
666 Third Avenue, 28th floor
New York, NY 10017
USA

Facsimile:    (212) 450-1535
Attention:    Mr. Ed McDermott Jr.
President

12

--------------------------------------------------------------------------------

Copies to:

Ludwig Institute for Cancer Research Ltd
666 Third Avenue, 28th floor
New York, NY 10017
USA

Facsimile:    (212) 450-1535
Attention:    Jonathan Skipper, Ph.D.
Executive Director, Technology Development

Notices to 4AB shall be addressed to:

4-Antibody AG
Schwarzwaldallee 215
Basel
CH-4002
Switzerland
Attention:     Robert F Burns, PhD
Chief Executive Officer

Copies to:

4-Antibody AG
Schwarzwaldallee 215
Basel
CH-4002
Switzerland

Attention:    Sarah Thompson, PhD
Head of Intellectual Property

21    FORCE MAJEURE

21.01
No failure or omission by the parties hereto in the performance of any
obligation under this Agreement shall be deemed a breach hereto or create any
liability if the same arises from any cause beyond the control of the parties
including, but not limited to, the following: acts of gods, acts or omissions of
any government; any rule, regulation or order issued by governmental authority
or by any officer, department, agency or instrumentality thereof: fire; storm;
flood; earthquake; accident; war; rebellion; insurrection; riot; invasion; or
strike, lockout or other work stoppage provided that such failure or omission is
cured as is practicable after the occurrence of the force majeure.

22    ENTIRE AGREEMENT

22.01
This Agreement, together with any Appendix attached hereto and expressly
incorporated herein, constitutes the entire agreement between the parties and
supersedes all previous arrangements whether written or oral. Any Amendment or
modification to this Agreement shall be of no effect unless made in a writing
which specifically references this Agreement and signed by both parties.

13

--------------------------------------------------------------------------------

IN WITNESS WHEREOF the parties, intending to be bound hereby, have caused their
duly authorised representatives to execute this Agreement.

LUDWIG INSTITUTE FOR CANCER RESEARCH        4-ANTIBODY AG

/s/ Edward A. McDermott____________________        /s/ Robert F.
Burns_____________________

Name: Edward A. McDermott                    Name: Robert F. Burns

Title: President                            Title: CEO

Date: May 23, 2011                        Date:    19th May 2011

/s/ Jonathan Skipper_________________________        /s/ Ulf Grawunder,
PhD_________________

Name: Jonathan Skipper                    Name: Ulf Grawunder, PhD

Title: Executive Director, Technology Development        Title:    CSO

Date: May 23, 2011                        Date: 19th May 2011

14

--------------------------------------------------------------------------------

Appendix 1.

PROGRAM SUMMARY

The parties will conduct preclinical and clinical research to establish
potential antibody immunotherapies in cancer. [**].

[**]:

1)    [**]
2)    [**]
3)    [**]
4)    [**]
5)    [**]
6)    [**]
7)    [**]
8)    [**]

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the Commission.

15

--------------------------------------------------------------------------------

Appendix 2:

TARGETS: the parties have jointly identified an initial list of potential
targets of clinical interest. Antibody immunotherapy against each of these
targets has potential utility in the treatment of cancer patients. These targets
are as follows:

1. GITR

2. OX40

3. TIM3

4. [**]

The parties may agree to change the list of targets, or to add further targets
to this list.

[**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed
separately with the Commission.

16

--------------------------------------------------------------------------------

Appendix 3:

JOINT MANAGEMENT COMMITTEE

4AB: Ulf Grawunder, Marc van Dijk (project coordinator), Robert Burns

LICR: Gerd Ritter, Jedd Wolchok, Jonathan Skipper/Pär Olsson (alternating)

17

--------------------------------------------------------------------------------

Appendix 4:    Material Transfer Agreement

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Postfach, 8024 Zurich, Switzerland
MATERIAL TRANSFER AGREEMENT
FOR ACADEMIC INSTITUTIONS

Name of Institution:                                201_

(The ‘Recipient’)

Address:

Phone:

Fax:

Email:
Attention:

(The ‘Investigator’)

Reagent:
Dear Dr ___
The Ludwig Institute for Cancer Research (hereinafter ‘LICR’) is willing to
provide your Institution, (the ‘Recipient’) with the reagents listed above (said
reagent and progeny thereof being referred to herein collectively as the
‘Reagents’) for use in the project described in Appendix A (‘Project’) upon the
terms and conditions set forth herein:

NOW THEREFORE, intending to be legally bound, the parties hereto hereby agree as
follows:

1.
The Reagents furnished to the Recipient for use by the Investigator pursuant to
this letter agreement and derivatives thereof (including but not limited to
recombinant constructs, cultures, subcultures, mutations or other products
derived directly or indirectly from the Reagents, referred to herein as the
‘Derivatives’) will be maintained at the Recipient within the sole possession
and control of the Investigator and those staff directly supervised by the
Investigator and will be used solely for research and/or educational purposes
described in the Project. The Reagents and any Derivatives will only be used in
laboratory animals or in vitro experiments as described above, will not be used
in therapy involving humans. The Reagents and Derivatives will not be sold by
the Recipient or the Investigator or any of Recipient’s or Investigator’s staff
to any third party, for any purposes whatsoever and will not be distributed, or
transferred by the Recipient or the Investigator or any of Recipient’s or
Investigator’s staff to any third party, for any purposes whatsoever without the
prior written agreement of LICR. No right, title or interest in the Reagents,
Information and the intellectual proprietary rights therein is conveyed under
this agreement except for the limited right to perform the Project.

2.
The Reagents, and any information relating to the Reagents that may be disclosed
to the Investigator by LICR (the ‘Information’) are being provided to and
accepted by the Recipient and the Investigator WITHOUT ANY REPRESENTATION OR
WARRANTY, ALL OF WHICH ARE EXPRESSLY DISCLAIMED, INCLUDING ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR ANY OTHER WARRANTY,
EXPRESSED OR IMPLIED. LICR and its directors, officers, employees or agents
assume no liability in connection with the Reagents or the Derivatives or the
Information or their use by the Recipient, including the Investigator and staff.
Recipient hereby agrees to defend, indemnify and hold harmless LICR and its
directors, officers,

18

--------------------------------------------------------------------------------

employees and agents from and against any liability or claim arising from any
use or misuse of the Reagents, Information or the Derivatives, breach of this
agreement or the negligence or wilful malfeasance of Recipient, the Investigator
or any of Recipient’s or Investigator’s staff. Without limiting the foregoing,
LICR makes no representations or warranties as to testing of the Reagents for
the presence or absence of any pathogens, and the Investigator and Recipient
assume all risk of harm with respect to any pathogens.

3.
Reagents are being provided at no cost to Recipient; provided, however, the
costs of handling and transportation by courier will be paid by Recipient, which
hereby gives authorisation to LICR to use the following courier account.

Courier:                    
Account No:                     

4.
The Investigator and Recipient have not licensed, assigned or otherwise
transferred and will not license, assign or otherwise transfer to any third
party any interest in the research involving the Reagents or in the intellectual
property or inventions that might emerge therefrom.

5.
Title to the Reagents and patent rights and other intellectual property rights
therein are retained by LICR. No right or license is granted with respect to the
Reagents, any Derivatives, the Information or any intellectual property rights,
except as expressly set forth herein.

6.
Recipient represents and warrants that it is a not-for-profit private or public
institution or academic entity and shall not use the Reagents or Information,
directly or indirectly for commercial purposes, including without limitation
sponsored research. In the event Recipient, Investigator or any other person
conceives or reduces to practice any invention as a result of the use of the
Reagents or Information furnished under this agreement or the intellectual
proprietary rights therein, including any new use for the Reagent, Recipient
will promptly disclose any such inventions, discoveries or new use to LICR in
writing (the “Invention Notice”). Inventorship on any corresponding patent
applications filed as a result of such inventions and discoveries shall be
determined in accordance with applicable laws governing inventorship. If
Recipient does not pursue or abandons patent protection for any invention
described in an Invention Notice, Recipient shall promptly notify LICR, and LICR
shall thereafter have the right, at its expense, to prepare, file, prosecute,
and maintain any such patent. Recipient and Investigator shall assist LICR, at
LICR’s expense, in the preparation of all documents necessary to effectuate
LICR's rights in such intellectual property. Recipient hereby grants LICR and
said third party a non-terminable, transferable, fully paid-up, royalty-free
worldwide, non-exclusive, sublicensable license under any intellectual property
rights therein. In addition, Recipient hereby grants LICR (or its designee) an
option to obtain a worldwide, exclusive, sublicensable license under any such
intellectual property rights within six (6) months of notification, on terms and
conditions to be negotiated in good faith by the parties. Such option may be
exercised by LICR (or its designee) within six (6) months after LICR’s receipt
of the Invention Notice.

7.
The Investigator will keep LICR informed of the results obtained during the
course of the research undertaken with the Reagents, any Derivatives and the
Information in the course of the Project and will provide the Intellectual
Property Office of LICR (666 Third Avenue, 28th Floor, New York, NY 10017, USA,
for the attention of Dr. Jonathan Skipper) with ongoing reports on a three
monthly basis and an Invention Notice promptly when an invention is made.

8.
LICR and the Recipient will keep in strict confidence all confidential
information it receives under this agreement and information relating to the
Project and will not publicly disclose any such information without the consent
of the other party, unless such information is or becomes generally known to the
public through no fault of either party, or is made available to the parties by
a third party having lawful right to do so, or is required to be disclosed (but
only to

19

--------------------------------------------------------------------------------

the extent of such requirement) pursuant to any law, court order or legal or
regulatory process, or is independently developed by the receiving party without
use of or reference to the confidential information of the disclosing party.
However, the Recipient and the Investigator shall have the right to publish and
present scientific findings relating to the results of the Project provided that
the Recipient and the Investigator provide LICR with copies of such proposed
disclosures at least thirty (30) days prior to submission for publication or
presentation. Within thirty (30) days of receipt of such proposed publication or
presentation, LICR shall advise Recipient whether patent or commercial interests
may be prejudiced by the proposed publication or presentation and shall have the
right to request delay of submission of the publication or presentation for an
additional period, not to exceed sixty (60) days from initial receipt by LICR,
to allow Recipient, who shall have the right but not the obligation in
accordance with paragraph 6 above, to seek appropriate intellectual property
protection of any inventions or discoveries relating to the Reagents or any
Derivatives. If LICR has not responded to the Recipient within the thirty (30)
day time period, the proposed publication or presentation shall be deemed not to
prejudice any patent or commercial interests and the Recipient is free to
proceed with the planned disclosure.

9.
Any publication referring to the Reagents, Information, any Derivatives or
reporting of the research carried out with the Reagents, Information or any
Derivatives shall contain a reference, when appropriate, to the relevant
publication describing the Reagents and to LICR as the source of the Reagents.
LICR would appreciate receiving, in due course, a copy of any relevant
publications.

Very truly yours,

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

By:                            By:                
Jonathan Skipper Ph.D.
Executive Director
Ludwig Institute for Cancer Research Ltd
666 Third Avenue 28th Floor
New York, NY 10017
USA

To be signed by authorised signatory of Recipient Institution:

Accepted and agreed to this

__________ Day of ________________ 201_

Signature ________________________
Name ___________________________
(Please Print)
Title ____________________________

To be signed by the Investigator:

Agreed and accepted this

_________ Day of _________________ 201_

20

--------------------------------------------------------------------------------

Signature _________________________
Name ____________________________
(Please Print)
Title _____________________________

21